[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA30053B1 - Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires . - Google Patents

Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires .

Info

Publication number
MA30053B1
MA30053B1 MA31035A MA31035A MA30053B1 MA 30053 B1 MA30053 B1 MA 30053B1 MA 31035 A MA31035 A MA 31035A MA 31035 A MA31035 A MA 31035A MA 30053 B1 MA30053 B1 MA 30053B1
Authority
MA
Morocco
Prior art keywords
cancer
treatment
ikk
thiophen
pyrimidin
Prior art date
Application number
MA31035A
Other languages
English (en)
Inventor
Karl Robert Dahnke
Ho-Shen Lin
Chuan Shih
Q May Wang
Bo Zhang
Michael Enrico Richett
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA30053B1 publication Critical patent/MA30053B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des composés de formule (I) : utilisables pour le traitement du cancer et des maladies inflammatoires.
MA31035A 2005-11-18 2008-06-13 Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires . MA30053B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
MA30053B1 true MA30053B1 (fr) 2008-12-01

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31035A MA30053B1 (fr) 2005-11-18 2008-06-13 Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires .

Country Status (27)

Country Link
US (1) US7547691B2 (fr)
EP (1) EP1989200B1 (fr)
JP (1) JP2009516697A (fr)
KR (1) KR100990771B1 (fr)
CN (1) CN101309918B (fr)
AR (1) AR057911A1 (fr)
AT (1) ATE437873T1 (fr)
AU (1) AU2006337626B2 (fr)
BR (1) BRPI0618245A2 (fr)
CA (1) CA2629336A1 (fr)
CR (1) CR9947A (fr)
DE (1) DE602006008187D1 (fr)
DK (1) DK1989200T3 (fr)
EA (1) EA014426B1 (fr)
EC (1) ECSP088456A (fr)
ES (1) ES2329085T3 (fr)
IL (1) IL190489A0 (fr)
MA (1) MA30053B1 (fr)
NO (1) NO20082594L (fr)
PE (1) PE20070833A1 (fr)
PL (1) PL1989200T3 (fr)
PT (1) PT1989200E (fr)
SI (1) SI1989200T1 (fr)
TN (1) TNSN08227A1 (fr)
TW (1) TW200800201A (fr)
WO (1) WO2007092095A2 (fr)
ZA (1) ZA200803940B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007117399A2 (fr) 2006-03-31 2007-10-18 Janssen Pharmaceutica N.V. Benzoimidazol-2-yl pyrimidines et pyrazines modulatrices du récepteur de l'histamine h4
EP2044061A2 (fr) * 2006-07-20 2009-04-08 Mehmet Kahraman Inhibiteurs de la rho kinase à base de benzothiophène
AU2007334039B2 (en) * 2006-12-21 2012-02-16 Eli Lilly And Company Imidazolidinonyl aminopyrimidine compounds for the treatment' of cancer
ES2351371T3 (es) 2006-12-21 2011-02-03 ELI LILLY & COMPANY Compuestos de imidazolidinonil aminopirimidina para el tratamiento del cáncer .
JP5204838B2 (ja) 2007-05-16 2013-06-05 イーライ リリー アンド カンパニー トリアゾリルアミノピリミジン化合物
AU2008254319B2 (en) 2007-05-16 2012-04-19 Eli Lilly And Company Triazolyl aminopyrimidine compounds
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
EP2310012B1 (fr) 2008-06-30 2015-03-04 Janssen Pharmaceutica N.V. Procédé pour la préparation de dérivés de pyrimidine substitués
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
US20130035326A1 (en) 2009-08-19 2013-02-07 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
MY159995A (en) 2010-04-27 2017-02-15 Hutchison Medipharma Ltd Pyrimidinyl indole compounds
EP2694707B1 (fr) 2011-04-07 2018-08-15 Cornell University Monomères aptes à dimériser dans une solution aqueuse et leurs procédés d'utilisation
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
EP2812324B1 (fr) 2012-02-08 2021-09-01 Sunovion Pharmaceuticals Inc. Composés hétéroaryles et procédé d'utilisation correspondant
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Ｋｒａｓ ｇ１２ｃ之抑制劑
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
WO2017076888A1 (fr) * 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv Acides 2-[3-(1-méthyl-pipéridin-4-yl)-propylamino]-pyrimidine-5-carboxyliques et amides et leurs procédés de fabrication
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
AU2017301767A1 (en) 2016-07-29 2019-02-14 Pgi Drug Discovery Llc Compounds and compositions and uses thereof
WO2018140513A1 (fr) 2017-01-26 2018-08-02 Araxes Pharma Llc Dérivés de 1-(3-(6-(3-hydroxynaphtalen-1-yl)benzofuran-2-yl)azétidin-1yl)prop-2-en-1-one et composés similaires utilisés en tant que modulateurs de kras g12c pour le traitement du cancer
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
EP3573964A1 (fr) * 2017-01-26 2019-12-04 Araxes Pharma LLC Composés à base de benzothiophène et de benzothiazole et leurs procédés d'utilisation
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
EA202090414A1 (ru) 2017-08-02 2020-05-28 Суновион Фармасьютикалз Инк. Соединения и их применение
EP3829580A1 (fr) 2018-08-01 2021-06-09 Araxes Pharma LLC Composés hétérocycliques spiro et procédés d'utilisation correspondants pour le traitement du cancer
MX2021010880A (es) 2019-03-14 2022-01-18 Sunovion Pharmaceuticals Inc Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3752589A (en) * 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
EP1831207B1 (fr) * 2004-12-17 2012-11-14 Amgen Inc. Composes d'aminopyrimidine comme inhibiteurs de plk

Also Published As

Publication number Publication date
NO20082594L (no) 2008-06-10
BRPI0618245A2 (pt) 2011-08-23
ECSP088456A (es) 2008-06-30
DE602006008187D1 (de) 2009-09-10
AU2006337626A8 (en) 2008-06-19
WO2007092095A2 (fr) 2007-08-16
PT1989200E (pt) 2009-10-12
ZA200803940B (en) 2009-09-30
KR20080059451A (ko) 2008-06-27
SI1989200T1 (sl) 2009-12-31
EA200801362A1 (ru) 2009-02-27
ES2329085T3 (es) 2009-11-20
DK1989200T3 (da) 2009-11-09
EA014426B1 (ru) 2010-12-30
PL1989200T3 (pl) 2009-12-31
PE20070833A1 (es) 2007-08-27
AU2006337626B2 (en) 2012-03-22
CN101309918B (zh) 2010-12-29
JP2009516697A (ja) 2009-04-23
KR100990771B1 (ko) 2010-10-29
US20080306082A1 (en) 2008-12-11
US7547691B2 (en) 2009-06-16
TNSN08227A1 (en) 2009-10-30
CR9947A (es) 2008-11-28
EP1989200B1 (fr) 2009-07-29
CN101309918A (zh) 2008-11-19
EP1989200A2 (fr) 2008-11-12
ATE437873T1 (de) 2009-08-15
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (fr) 2007-08-16
TW200800201A (en) 2008-01-01
IL190489A0 (en) 2008-11-03
AR057911A1 (es) 2007-12-26
WO2007092095A3 (fr) 2007-11-08

Similar Documents

Publication Publication Date Title
MA30053B1 (fr) Derives [4-(benzo[b]thiophen-2-yl)-pyrimidin -2-yl]-amine en tant qu'inhibiteurs de ikk-beta pour le traitement du cancer et de maladies inflammatoires .
MA31574B1 (fr) Dérivés de pyrazole et leur utilisation comme inhibiteurs de raf
SV2009003233A (es) Derivados de 2-(1-fenil -5- hidroxi -4alfa-metil-hexahidrociclopenta (f)indazol-5- il)etil fenilo como ligandos del receptor glucocorticoide
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA31170B1 (fr) Dérivés de 2-amino-5,7-dihydro-6h-pyrrolo[3,4-d]pyrimidine servant d'inhibiteurs de la hsp-90 pour le traitement du cancer
HRP20050533A2 (en) Aminoindazole derivatives and use thereof as kinase inhibitors
MA31903B1 (fr) Derives de thiazole utilises comme inhibiteur de la pi 3 kinase
MXPA05011166A (es) Antagonistas del receptor del peptido relacionado con el gen de la calcitonina.
NO20063821L (no) Kinolinderivater for anvendelse som mykobakterielle inhibitorer
YU90801A (sh) Supstituisani benzimidazoli
YU37904A (sh) Benzimidazoli kao korisni inhibitori proteinske kinaze
MEP60608A (en) INDOLE OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IkappaB KINASE
MA27771A1 (fr) 5,7-diaminopyrazolo[4,3-d]pyrimidines utiles dans le traitement de l'hypertension
EA200801996A1 (ru) 2-замещенные производные 4-бензилфталазинонов в качестве гистаминовых h1- и h3-антагонистов
MA30709B1 (fr) Derives de pyrido (2, 3-d) pyrimidinone et leur utilisation comme inhibiteurs de pi3.
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
MA29330B1 (fr) Antagonistes de recepteur de pgd2 pour le traitement des maladies inflammatoires.
GEP20146131B (en) Carbazole compounds and therapeutic uses thereof
ATE466860T1 (de) Cgrp-rezeptorantagonisten
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
PE20081496A1 (es) Derivados de 2,5-dihidro-3-h-pirazolo[4,3-c]piridazin-3-ona sustituidos como antagonistas de los receptores cb1
NO20055632L (no) Aromatiske oksyfenyl- og aromatiske sulfanylfenylderivater
ATE467636T1 (de) Pyrazoloä3 , 4-düazepinderivate als histamin-h3- antagonisten
ATE517873T1 (de) 6-oxo-1,6-dihydropyrimidin-2-yle bei der behandlung proliferativer krankheiten
ATE492534T1 (de) 1h-indol-5-ylpiperazin-1-ylmethanonderivate